Bruker (NASDAQ:BRKR) PT Lowered to $60.00 at The Goldman Sachs Group

Bruker (NASDAQ:BRKR – Free Report) had its price objective trimmed by The Goldman Sachs Group from $72.00 to $60.00 in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a sell rating on the medical research company’s stock. Several other equities research analysts have also issued reports on BRKR. Stifel Nicolaus […]

Leave a Reply

Your email address will not be published.

Previous post Avis Budget Group (NASDAQ:CAR) Price Target Cut to $120.00
Next post Reviewing Urgent.ly (ULY) and Its Rivals